Caxton Associates LLP Trims Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Caxton Associates LLP decreased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 67.7% during the first quarter, HoldingsChannel reports. The fund owned 49,308 shares of the biotechnology company’s stock after selling 103,444 shares during the quarter. Caxton Associates LLP’s holdings in BioMarin Pharmaceutical were worth $2,785,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in BMRN. CIBC Private Wealth Group LLC boosted its holdings in shares of BioMarin Pharmaceutical by 38.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 179 shares during the period. Northwestern Mutual Investment Management Company LLC raised its stake in shares of BioMarin Pharmaceutical by 0.4% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock valued at $2,554,000 after purchasing an additional 183 shares during the period. Nisa Investment Advisors LLC lifted its holdings in BioMarin Pharmaceutical by 7.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 195 shares in the last quarter. Caerus Investment Advisors LLC lifted its holdings in BioMarin Pharmaceutical by 2.8% during the 4th quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company’s stock worth $608,000 after purchasing an additional 278 shares in the last quarter. Finally, Chicago Partners Investment Group LLC boosted its stake in BioMarin Pharmaceutical by 2.4% in the 1st quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock worth $660,000 after purchasing an additional 290 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 3,281 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $53.85, for a total value of $176,681.85. Following the completion of the sale, the executive vice president directly owned 51,818 shares of the company’s stock, valued at $2,790,399.30. The trade was a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.68% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BMRN shares. The Goldman Sachs Group initiated coverage on shares of BioMarin Pharmaceutical in a report on Monday, May 11th. They issued a “neutral” rating and a $69.00 price target on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Citigroup increased their target price on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Morgan Stanley cut their price target on shares of BioMarin Pharmaceutical from $120.00 to $119.00 and set an “overweight” rating for the company in a report on Tuesday, May 5th. Finally, UBS Group reaffirmed a “neutral” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $88.26.

BioMarin Pharmaceutical Trading Up 0.8%

BMRN stock opened at $59.33 on Friday. The company has a market capitalization of $11.47 billion, a PE ratio of 43.31, a price-to-earnings-growth ratio of 0.45 and a beta of 0.24. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.20 and a current ratio of 5.81. BioMarin Pharmaceutical Inc. has a one year low of $49.26 and a one year high of $66.28. The company’s 50 day moving average price is $56.54 and its two-hundred day moving average price is $56.84.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.